Artiva Biotherapeutics Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
134
- Stock Symbol
-
ARTV
- Share Price
-
$4.01
- (As of Friday Closing)
Artiva Biotherapeutics General Information
Description
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
Contact Information
Website
www.artivabio.comCorporate Office
- 5505 Morehouse Drive
- Suite 100
- San Diego, CA 92121
- United States
Corporate Office
- 5505 Morehouse Drive
- Suite 100
- San Diego, CA 92121
- United States
Artiva Biotherapeutics Timeline
Artiva Biotherapeutics Stock Performance
As of 13-Nov-2026, Artiva Biotherapeutics’s stock price is $4.01. Its current market cap is $198M with 49.4M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.01 | $3.96 | $2.96 - $14.53 | $198M | 49.4M | 712K | -$2.85 |
Artiva Biotherapeutics Financials Summary
As of 30-Sep-2026, Artiva Biotherapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 8,553 | (5,979) | 113,173 | |
| Revenue | 0 | 0 | 251 | 33,492 |
| EBITDA | (102,438) | (87,227) | (61,097) | (27,893) |
| Net Income | (98,115) | (83,865) | (58,179) | (32,766) |
| Total Assets | 342,975 | 130,940 | 209,581 | 105,114 |
| Total Debt | 9,171 | 10,942 | 14,354 | 16,912 |
Artiva Biotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Artiva Biotherapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Artiva Biotherapeutics Comparisons
Industry
Financing
Details
Artiva Biotherapeutics Competitors (8)
One of Artiva Biotherapeutics’s 8 competitors is Fate Therapeutics, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Fate Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Poseida Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Nkarta Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Allogene Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Compass Therapeutics | Formerly VC-backed | Boston, MA |
Artiva Biotherapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Artiva Biotherapeutics Patents
Artiva Biotherapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026198528-A1 | Treatment of b-cell associated rheumatologic diseases with nk cells | Pending | 17-Mar-2025 | ||
| WO-2026006481-A1 | Treatment of autoimmune disorders with nk cells and cd38 antibody | Pending | 26-Jun-2024 | ||
| EP-4727574-A2 | Chimeric antigen receptors and use thereof | Pending | 14-Jun-2023 | ||
| WO-2024259070-A2 | Chimeric antigen receptors and use thereof | Inactive | 14-Jun-2023 | ||
| WO-2024259070-A3 | Chimeric antigen receptors and use thereof | Inactive | 14-Jun-2023 | A61K40/31 |
Artiva Biotherapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Artiva Biotherapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Artiva Biotherapeutics FAQs
-
When was Artiva Biotherapeutics founded?
Artiva Biotherapeutics was founded in 2018.
-
Where is Artiva Biotherapeutics headquartered?
Artiva Biotherapeutics is headquartered in San Diego, CA.
-
What is the size of Artiva Biotherapeutics?
Artiva Biotherapeutics has 134 total employees.
-
What industry is Artiva Biotherapeutics in?
Artiva Biotherapeutics’s primary industry is Drug Discovery.
-
Is Artiva Biotherapeutics a private or public company?
Artiva Biotherapeutics is a Public company.
-
What is Artiva Biotherapeutics’s stock symbol?
The ticker symbol for Artiva Biotherapeutics is ARTV.
-
What is the current stock price of Artiva Biotherapeutics?
As of 13-Nov-2026 the stock price of Artiva Biotherapeutics is $4.01.
-
What is the current market cap of Artiva Biotherapeutics?
The current market capitalization of Artiva Biotherapeutics is $198M.
-
Who are Artiva Biotherapeutics’s competitors?
Fate Therapeutics, Poseida Therapeutics, Nkarta Therapeutics, Allogene Therapeutics, and Compass Therapeutics are some of the 8 competitors of Artiva Biotherapeutics.
-
What is Artiva Biotherapeutics’s annual earnings per share (EPS)?
Artiva Biotherapeutics’s EPS for 12 months was -$2.85.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
